It modulates the response to the virus at the level of the immune system, and is used to treat an infection.

We conducted an experimental protocol with a nasal recombinant IFNα-2b formulation (Nasalferon) in 12 healthy volunteers who received 1 MIU per nostril twice a day, three consecutive days, and studied the induction of biomarkers related to antiviral and immune responses. Nasalferon increases the antiviral biomarker OAS1 transcript levels in oropharynx and PBMCs, regulates molecular and cellular elements related to innate and adaptive immune responses and decreases granulocytes population. These effects support Nasalferon use in virally-exposed populations.

Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood

Cuba will start applying Nasalferon to travelers and live-in family members

In Cuba, All International Travelers to Receive Nasalferon

An Experience with Cuban Biotech’s Nasalferon to Prevent SARS-COV-2 Infections in International Travelers and their Contacts

Meanwhile “free” countries are destroying the lives of millions of people by pretending covid doesn’t exist anymore, and paxlovid is $1000 dollars and doctors don’t want to prescribe it because covid is “mild”.

  • HexBroke [any, comrade/them]@hexbear.net
    link
    fedilink
    English
    arrow-up
    4
    ·
    9 months ago

    These is at a higher dose but gives you a sense:

    Although frequently effective, IFNα induces a variety of neuropsychiatric adverse effects, including an acute confusional state that develops rapidly after initiation of high-dose IFNα, a depressive syndrome that develops more slowly over weeks to months of treatment, and manic conditions most often characterised by extreme irritability and agitation, but also occasionally by euphoria. Acute IFNα-induced confusional states are typically characterised by disorientation, lethargy, somnolence, psychomotor removedation, difficulties with speaking and writing, parkinsonism and psychotic symptoms. Strategies for managing delirium should be employed, including treatment of contributing medical conditions, use of either typical or atypical antipsychotic agents and avoidance of medications likely to worsen mental status. Significant depressive symptoms occur in 21–58% of patients receiving IFNα, with symptoms typically manifesting over the first several months of treatment. The most replicated risk factor for developing depression is the presence of mood and anxiety symptoms prior to treatment.

    A vaccine trains your immune system to respond, and interferon therapy is throwing the immune system into DEFCON 1

    Useful and an achievement for Cuba but still worse than other social interventions